UltraMIST therapy is a no-contact, low-frequency ultrasound therapy that has been clinically proven to promote healing across a wide range of chronic and acute wounds. 

No contact Low-Frequency Ultrasound

For patients who suffer from either acute or chronic wounds, any delay in healing increases the risk to patients’ overall health and quality of life. It also places a significant burden on the healthcare system. Typical wound management protocols can be successful in some cases. However, depending upon wound-specific characteristics, chronicity, and comorbidities, standard protocols leave many other patients with chronic wounds that do not heal. By choosing an energy-first approach and making UltraMIST® System your first-line treatment for advanced wounds, you give your patients a high chance for improvement and ultimately, healing their wounds.

In a meta-analysis of preclinical and clinical evidence* for advanced wound closure ultrasound healing therapy achieved an 85% AREA REDUCTION IN 7 WEEKS across a wide range of chronic and acute wounds 

Medicare Coverage Guidance for UltraMIST®

Low-frequency, non-contact, non-thermal ultrasound (MIST Therapy) will be considered reasonable and necessary wound therapy and therefore eligible for coverage by Medicare when provided for any of the following clinical conditions: 

• Wounds and ulcers which are too painful for sharp or excisional debridement and have failed conventional debridement with documentation supporting the same. 

• Wounds and ulcers meeting Medicare coverage for debridement but with documented contraindications to sharp or excisional debridement. 

• Wounds and ulcers meeting Medicare coverage for debridement but with documented evidence of no signs of improvement after 30 days of standard wound care. 

Coverage for Low Frequency, non-contact, non-thermal ultrasound is as follows:

• Low-frequency, non-contact, non-thermal ultrasound (MIST Therapy) must be provided two (2) to three (3) times per week to be considered reasonable and necessary. The length of individual treatments will vary per wound size.

• Observable, documented improvements in the wound(s) should be evident after six (6) treatments. Improvements include documented reduction in pain, necrotic tissue, wound size; or improved granulation tissue. Continuing treatments for wounds demonstrating no improvement after six (6) treatments is considered not reasonable and necessary.

• No more than eighteen (18) treatments within a six-week period will be considered reasonable and necessary.  This type of therapy is included in the payment for the treatment of the same wound with other active wound care management or wound debridement. Low frequency, non-contact, non-thermal ultrasound treatments would be separately billable if other active wound management and/or wound debridement is not performed.

This type of therapy is included in the payment for the treatment of the same wound with other active wound care management or wound debridement. Low frequency, non-contact, non-thermal ultrasound treatments would be separately billable if other active wound management and/or wound debridement is not performed.

Improvements may include documented reduction in pain, necrotic tissue, wound size; or improved granulation tissue.

Related therapy